Patient Capital Management, LLC: ROYALTY PHARMA PLC (RPRX): Quarterly 13F Position History
As of Q2 2026, Patient Capital Management, LLC reported 3,598,808 shares of ROYALTY PHARMA PLC (RPRX), worth $201.8M and representing 6.7% of its 13F equity book. Quarter-over-quarter share count change: 44,908 (-1.2%) . The position first appeared in Q4 2023 and has been disclosed across 11 13F-HR filings in Pactolio's tracked window.
- 3,598,808Shares Held (Latest Filing)
- $201.8MReported Market Value (Latest Filing)
- 6.7%Portfolio Weight (% of 13F Equity Book)
- 44,908Quarter-over-Quarter Share Change
- +$27.0MQuarter-over-Quarter Value Change
- 3,643,716Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 11 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q2 2026 | 3,598,808 | 44,908 | -1.2% | $201.8M | 6.7% | $56.1 |
| Q1 2026 | 3,643,716 | +310,041 | +9.3% | $174.8M | 6.5% | $48.0 |
| Q4 2025 | 3,333,675 | +215,825 | +6.9% | $128.8M | 5.0% | $38.6 |
| Q3 2025 | 3,117,850 | +129,862 | +4.3% | $110.0M | 4.4% | $35.3 |
| Q2 2025 | 2,987,988 | +15,342 | +0.5% | $107.7M | 4.9% | $36.0 |
| Q1 2025 | 2,972,646 | +97,557 | +3.4% | $92.5M | 4.8% | $31.1 |
| Q4 2024 | 2,875,089 | +833,894 | +40.9% | $73.3M | 3.4% | $25.5 |
| Q3 2024 | 2,041,195 | +616,805 | +43.3% | $57.7M | 2.8% | $28.3 |
| Q2 2024 | 1,424,390 | +4,572 | +0.3% | $37.6M | 2.0% | $26.4 |
| Q1 2024 | 1,419,818 | +165,038 | +13.2% | $43.1M | 2.1% | $30.4 |
| Q4 2023 | 1,254,780 | – | – | $35.2M | 1.9% | $28.1 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares, a quarter-end mark rather than the manager's cost basis. See the full methodology document for the normalization rules.
When did Patient Capital Management, LLC first disclose a RPRX position in 13F-HR filings?
Patient Capital Management, LLC first reported ROYALTY PHARMA PLC (RPRX) on its 13F-HR filing for the period ending 2023-12-31 (Q4 2023). The position has appeared on 11 reported quarters within Pactolio's tracked window.
What was Patient Capital Management, LLC's most recent quarter-over-quarter share-count change in RPRX?
Between Q1 2026 and Q2 2026, Patient Capital Management, LLC reduced its RPRX position by 44,908 shares (-1.2%), leaving 3,598,808 shares at a market value of $201.8M.
Does the implied price-per-share represent Patient Capital Management, LLC's cost basis in RPRX?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.